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ABSTRACT
Objectives: To determine the effectiveness of early
assisted discharge for chronic obstructive pulmonary
disease (COPD) exacerbations, with home care
provided by generic community nurses, compared with
usual hospital care.
Design: Prospective, randomised controlled and
multicentre trial with 3-month follow-up.
Setting: Five hospitals and three home care
organisations in the Netherlands.
Participants: Patients admitted to the hospital with an
exacerbation of COPD. Patients with no or limited
improvement of respiratory symptoms and patients with
severe unstable comorbidities, social problems or those
unable to visit the toilet independently were excluded.
Intervention: Early discharge from hospital after 3 days
inpatient treatment. Home visits by generic community
nurses. Primary outcome measure was change in health
status measured by the Clinical COPD Questionnaire
(CCQ). Treatment failures, readmissions, mortality and
change in generic health-related quality of life (HRQL)
were secondary outcome measures.
Results: 139 patients were randomised. No difference
between groups was found in change in CCQ score at
day 7 (difference in mean change 0.29 (95% CI −0.03
to 0.61)) or at 3 months (difference in mean change
0.04 (95% CI –0.40 to 0.49)). No difference was found
in secondary outcomes. At day 7 there was a significant
difference in change in generic HRQL, favouring usual
hospital care.
Conclusions: While patients’ disease-specific health
status after 7-day treatment tended to be somewhat
better in the usual hospital care group, the difference
was small and not clinically relevant or statistically
significant. After 3 months, the difference had
disappeared. A significant difference in generic HRQL at
the end of the treatment had disappeared after 3 months
and there was no difference in treatment failures,
readmissions or mortality. Early assisted discharge with
community nursing is feasible and an alternative to usual
hospital care for selected patients with an acute COPD
exacerbation.
Trial registration: NetherlandsTrialRegister NTR 1129.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is a chronic disease with high prevalence,1
mortality and morbidity.2 3 Exacerbations of
ARTICLE SUMMARY
Article focus
▪ What is the effectiveness of early assisted discharge
with community nursing for chronic obstructive
pulmonary disease (COPD) exacerbations in com-
parison with usual hospital care as measured by
the Clinical COPD Questionnaire (CCQ).
Key messages
▪ There is no short-term or long-term difference in
change in health status as measured by the CCD.
▪ A significant difference in generic health-related
quality of life at the end of the treatment disap-
peared after 3 months.
▪ Early assisted discharge with home visits by
community nurses is a feasible and an alterna-
tive to usual hospital care for selected patients
with an acute exacerbation of their COPD.
Strength and limitations of this study
▪ One hundred and thirty-nine patients were rando-
mised where 165 was calculated to be the
required sample size. However, because the dif-
ference between the groups was only 0.29
instead of 0.4 it is unlikely that this difference
would have increased to the clinically relevant
difference of 0.4 with an additional 26 patients.
▪ This study is the first larger randomised con-
trolled trial on early assisted discharge in the
Dutch healthcare system.
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the disease have negative effects on patient outcomes 4–6
and are the main cause for hospitalisation.7
Hospitalisations are not only the main cost driver in
COPD, they also put pressure on scarce hospital beds,
especially during winters.8 Several studies have shown
that some patients with an exacerbation, who would
otherwise be admitted to the hospital, can be treated at
home safely after examination in the emergency depart-
ment or a short hospital admission.9–16 This is called
hospital-at-home. Hospital-at-home aims to avoid admis-
sion, or reduce length of stay (early assisted discharge
schemes). Previous studies found no differences in
readmissions, mortality and disease-specific quality of
life between hospital-at-home and usual hospital
care.9–11 15 16 Most published hospital-at-home studies
originate from the UK and Spain, where this service is
mainly provided by hospital-based respiratory nurses who
visit patients at home. Davison et al 17 and Nicholson
et al18 suggested the use of non-specialised ‘generic’ com-
munity nursing teams for home supervision to increase
the capacity of hospital-at-home schemes.
The Netherlands has a nation-wide, good infrastructure
for community nursing, which could be used for
hospital-at-home. Therefore we designed an early assisted
discharge hospital-at-home scheme for COPD exacerba-
tions, mainly operated by generic community nurses who
performed the home visits.19 Main objective of the GO
AHEAD study (GO AHEAD is the acronym for Assessment
Of Going Home under Early Assisted Discharge) was to
determine the effectiveness and cost-effectiveness of early
assisted discharge followed by community-based nursing
care at home. In addition, evaluation of patient satisfaction
and preferences, carer strain and preferences and an evalu-
ation among professional care providers were performed.
The focus of this paper is on the effectiveness of early
assisted discharge, with the Clinical COPD Questionnaire
(CCQ) as the primary outcome measure. In addition, treat-
ment failures, readmissions, mortality and generic quality
of life were assessed as secondary outcomes.
METHODS
GO AHEAD was a randomised controlled trial compar-
ing usual hospital care with early assisted discharge for
COPD exacerbations. Five hospitals and three home
care organisations participated. Treatment consisted of
7 days in-hospital care as usual or 3 days in-hospital treat-
ment followed by 4 days care at home. Patients were fol-
lowed until 3 months after randomisation.
All patients admitted to one of the participating hospi-
tals with a COPD exacerbation, as diagnosed by the
reviewing physician, were screened for potential eligibil-
ity on their first day of admission according to the inclu-
sion and exclusion criteria (table 1). On day 3 of
admission, clinical stability was assessed in patients who
gave written informed consent (see randomisation cri-
teria in table 1). For each hospital separately, participat-
ing patients were randomised on day 3 of admission, in
a 1:1 ratio using a block-size of 6. Randomisation was
performed by the study nurses. The randomisation
sequence was computer generated a priori by an inde-
pendent researcher. Allocation sequence was placed in
sealed envelopes. The study was approved by the Ethics
Table 1 Inclusion and exclusion criteria (applied at admission) and randomisation criteria (applied at day 3 of admission)
Inclusion criteria (checked on day 1) Exclusion criteria (checked on day 1)
Age ≥40 years Major uncontrolled co morbidity, including pneumonia that is
prominent, heart failure that is prominent or acute changes on ECG
and (suspected) underlying malignancy
Competent to give informed consent Mental disability, including dementia, impaired level of
consciousness and acute confusion
Diagnosed with COPD. COPD was defined as at least
GOLD stage I and 10 pack years of smoking
Living outside care region of the home care organisation
Hospitalisation for COPD exacerbation Inability to understand the programme
Indication for admission to intensive care unit or for non-invasive
ventilation
Active alcohol and/or drug abuse
Insufficient availability of informal care at home
Randomisation criteria (checked on day 3)
Completed Informed Consent on day three of admission
Acceptable general health:
▪ Decrease physical complaints
▪ Non-dependency of therapies that cannot be given at home (intravenous therapy and newly prescribed oxygen supply)
▪ Being able to visit toilet independently
Normal or moderately increased blood sugar levels, defined as ≤15 or ≥15 mmol/l but patient is capable to regulate blood
sugar levels independently
Respiratory complaints of dyspnoea, wheezing and rhonchi must have decreased in comparison with day of admission
COPD, chronic obstructive pulmonary disease.
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Committee of the Catharina Hospital, the Netherlands,
approval number M07-1755.
During the first 3 days of the admission all patients
were treated in the hospital according to the study
protocol.19 Treatment consisted of systemic corticoster-
oids, nebulised bronchodilators and antibiotics and
oxygen upon indication. Exacerbation symptoms were
scored each day. Physiotherapists visited all patients for
instruction of breathing and coughing techniques. On
the fourth day of admission all randomised patients
switched to oral medication and metered-dosed inhala-
tions. Patients randomised to early assisted discharge
were discharged home on the fourth day of admission
and further treated at home. Community nurses visited
or contacted the patient at least once daily on the day of
discharge and the three consecutive days. They contin-
ued to score exacerbation symptoms and provided
reassurance and counselling. Furthermore, medication
compliance and inhalation techniques were addressed.
Community nurses had the highest levels of generic
nursing training in the Netherlands. No additional train-
ing was provided for the trial. The nurses could contact
the hospital to discuss the patient’s condition. If neces-
sary, patients were readmitted to the hospital. For
patients a 24 h telephone access to the hospital respira-
tory ward was installed for emergencies.
Patients in the usual hospital care group received care
as usual at the discretion of the hospital staff. General
practitioners were informed about the patient’s partici-
pation in the trial and the discharge date. Clinical
responsibility during home care remained with the
respiratory physician. A detailed description of the
research protocol and the early assisted discharge inter-
vention has been published previously.19
Primary outcome was the change in CCQ scores
between baseline (T0=day 3 of admission) and the end of
the supervised treatment (T+4 days). The CCQ is a
disease-specific questionnaire measuring health status.20 It
consists of 10 questions in three domains: symptoms, func-
tional state and mental state, resulting in an overall,
continuous score varying from 6 (worst score) to 0 (best
score).20 In order to produce a valid overall score, three,
three and two questions on the symptoms domain, func-
tional state and mental state domain, respectively, need to
be answered. The CCQ has proved to be responsive to
change. The minimal clinical important difference is
0.4.21 Secondary outcomes were: (1) change in CCQ
scores between baseline and 3 months after randomisation
(T+90 days); (2) number of treatment failures (ie, either
death or clinical deterioration leading to prolonged hos-
pital stay beyond the standardised 7 days (usual hospital
care) or death or readmission during the 4 days treatment
at home (early discharge)); (3) mortality; (4) readmissions
during the 3 month follow-up and (5) generic health-
related quality of life measured by the EuroQol-5D
(EQ-5D)22 at baseline, T+4 days and T+90 days. Utilities
were calculated using the Dutch value set.22 Higher scores
represent better generic quality of life.
Statistical analysis
To detect a difference of 0.4 in CCQ change scores
between the two groups, in favour of the early discharge
group, with a power of 0.80 and α of 0.05, with SD in
the usual hospital care group of 0.922 and 0.988 in the
early discharge group, the required sample size was
165.19 Change in CCQ scores and EQ-5D scores was ana-
lysed using a linear repeated measures model with corre-
lated errors. An unstructured covariance matrix for the
residuals of the different measurements was used.
Backward selection of covariates was applied. In addition
to time (ie, measurement at T+4 days, end of treatment
and T+90 days, end of follow-up), the interaction of
time and treatment, the following variables were tested:
baseline CCQ or EQ-5D score, treatment centre, age,
gender, comorbidity,23 smoking status, living situation,
availability informal caregiver, presence of home care
prior to admission, course of oral corticosteroids and/or
antibiotics prior to admission. Variables were retained in
the model if their exclusion led to a 10% change in the
estimated treatment effect.24 For the analysis of CCQ
scores, only baseline score was included in the final
model. For the analysis of EQ-5D scores, baseline score,
comorbidity and gender were included. Results are pre-
sented as mean differences in change and 95% CI.
Numbers of patients with treatment failures, readmis-
sions and mortality were analysed using multiple logistic
regression analysis. Numbers of readmissions per patient
in each group were analysed in a Poisson regression.
Time to readmission was analysed with a Cox propor-
tional hazards model. Results are presented as OR or
HR with 95% CI. Again, backward selection was used to
select covariates. Only baseline CCQ score was retained
in the models. The significance level for a difference
between treatment groups was set at p≤0.05. All analyses
were performed using the Statistical Package for Social
Sciences (SPSS), V.17.0, IBM.
RESULTS
In total, 1371 patients were screened for eligibility
between November 2007 and March 2011, of whom 508
met the criteria for eligibility on day 1. Figure 1 shows
an overview of the patient flow during the trial from hos-
pital admission to the end of the follow-up. Three
patients in the early assisted discharge group and seven
in the usual hospital care group were not satisfied with
the allocated place of treatment and withdrew consent
immediately after randomisation. The total dropout over
the study period was 16%, 25% in the usual hospital
care group and 10% in the early assisted discharge
group. Baseline CCQ scores of patients dropping out
were not different from those who completed the study,
but they did have more comorbidities. At T+4 days 118
of 129 still participating patients produced a valid overall
score on the CCQ and were included in the analysis.
The other patients did not withdraw consent and contin-
ued to participate in the study in order to contribute to
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the other analyses and to produce a valid score at other
measuring points. This approach fits with the intention-
to-treat principle and the repeated measures analysis. At
T+90 days, 101 of 115 patients produced a valid overall
CCQ score.
Table 2 shows the baseline characteristics of rando-
mised patients by treatment group. These were compar-
able across the groups. At the end of follow-up period
lung function testing was performed by which classifica-
tion of disease severity according to the GOLD criteria2
could be made (see table 3).
Table 4 shows the unadjusted CCQ scores at the differ-
ent measuring points. At T0 CCQ scores were 2.22
(0.97) for the usual hospital care group and 2.63 (1.06)
for the early discharge group. Figure 2 shows the
change in CCQ scores from T0, adjusted for baseline
score. CCQ scores improved between T0 and T+4 days
for the usual hospital care group, and were almost stable
for the early assisted discharge group, but there was no
significant difference between the groups at T+4 days
(difference in mean change from T0 0.29, 95% CI
−0.03 to 0.61, p=0.078). At T+90 days, CCQ scores of
both groups were slightly higher in comparison with T0.
There was no difference between the groups at
3 months (difference in mean change from T0 0.04,
95% CI −0.40 to 0.49, p=0.858).
Treatment failed in five patients. One patient in the
early discharge group needed readmission to the hospital
because of deterioration of respiratory symptoms, before
the end of the home treatment and four patients in the
usual hospital care group required hospital admission
beyond the 7 days that were stated in the protocol (two
because of deterioration of respiratory symptoms, two
patients because of deterioration of general condition due
to gastroenteritis caused by norovirus). This difference was
not significant (OR early discharge group 0.27, 95% CI
0.026 to 2.70, p=0.263). Table 5 shows the number of read-
missions during follow-up. Seventeen patients in each
group had one or more readmission to the hospital of
which 14 first readmissions were due to an exacerbation or
other pulmonary indication (OR early discharge group
0.80, 95% CI 0.36 to 1.79, p=0.592). There was no differ-
ence in the number of readmissions per patient between
the groups, or in the total number of readmissions in each
group. There was no difference in time to first readmission
between the two groups (HR early discharge group 0.77,
95% CI 0.39 to 1.53, p=0.461).
No patient died during the hospital or home treat-
ment, but one patient from each group died during
follow-up. Cause of death was unknown in one case
(patient died during sleep at home) and an acute
abdomen in the other. Both were not related to the trial.
EQ-5D utility scores (SD) at T0 were 0.713 (0.22) for
the usual hospital care group and 0.664 (0.26) for the
early assisted discharge group. Table 6 shows the mean
changes and mean difference in change from baseline
of EQ-5D utility. In the usual hospital care group, mean
utility scores improved from T0 to T+4 days and
decreased to baseline at T+90 days. In the early assisted
discharge group mean utility scores remained close to
Figure 1 Patient flow through study.
*Not asked to participate because of logistical reasons (eg no study staff available or patient not admitted to respiratory ward).
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baseline. The mean change in utility scores on T+4 days
was significant greater in the usual hospital care group.
At T+90 days this difference between treatment groups
had disappeared.
DISCUSSION
This is the first randomised controlled trial that investi-
gated the effectiveness of early assisted discharge for
COPD exacerbations with supervision at home by com-
munity nurses. In addition, this is the first evaluation of
early discharge for this disease in the Dutch healthcare
system. While patients’ disease-specific health status as
expressed in the mean CCQ score after7 days treatment
tended to be somewhat better in the usual hospital care
group, the difference was small, not clinically relevant
and not statistically significant. After 3 months, the dif-
ference had disappeared. The same pattern was found
in generic health-related quality of life measured with
the EQ-5D, although this difference was statistically
significant at the end of the supervised treatment. The
difference had disappeared at the end of the 3-month
follow-up period. There was no difference in treatment
failures, readmissions or mortality.
Table 2 Baseline characteristics and treatment at admission
Characteristic
Usual hospital care
(N=69)
Early assisted discharge
(N=70)
Age (years) 67.8 (11.3) 68.3 (10.3)
Men n (%) 38 (55.1) 48 (68.6)
Smoking history
Current smokers n (%) 27 (39.1) 23 (32.9)
Pack years, median interquartile range 37 44
36.9 26.7
Body mass index (kg/m2) 25.6 (4.3) 25.0 (5.1)
Charlson comorbidity score*23 1.68 (1.1) 1.74 (1.1)
Comorbidity score of 1 n (%) 42 (60.0) 38 (54.0)
Comorbidity score >1 n (%) 27 (39.0) 32 (46.0)
Living situation
Living alone n (%) 21 (30.4) 22 (31.4)
Receiving care at home before admission n (%) 16 (23.2) 17 (24.3)
Treatment at admission
Long-term oxygen treatment n (%) 4 (5.8) 5 (7.1)
Oral steroids n (%) 5 (7.2) 10 (14.3)
Course of oral steroids prior to admission n (%) 34 (50.0) 35 (50.7)
Course antibiotics prior to admission n (%) 31 (45.6) 32 (46.4)
Inhaled β2-agonist (LABA) n (%) 9 (13.0) 7 (10.0)
Inhaled corticosteroid n (%) 3 (12.0) 3 (15.0)
Inhaled corticosteroid/LABA combination n (%) 44 (63.7) 50 (71.4)
Inhaled anticholinergic n (%)
Tiotropium 31 (44.9) 36 (51.4)
Ipratropium 12 (17.4) 13 (18.6)
Followed rehabilitation programme in year prior to admission n
(%)
10 (14.9) 12 (17.4)
Heart Rate (beats/min) 91.0 (14.2) 95.6 (18.4)
Arterial blood gas† N=37 N=42
pH 7.44 (0.05) 7.43 (0.04)
pO2 (mm Hg) 70.7 (13.2) 67.3 (8.1)
pCO2 (mm Hg) 37.2 (6.2) 39.1 (5.3)
Saturation 94 (2.5) 94 (3.6)
Values represent mean (SD), unless stated otherwise.
*Charlson comorbidity index, 1=only COPD, higher score means more comorbidities.
†Only data of blood gas measurements in patients without oxygen supplement.
COPD, chronic obstructive pulmonary disease; LABA, long-acting β2 agonist.
Table 3 Lung function testing at the end of 3-month
follow-up
Usual
hospital care
Early assisted
discharge
Postbronchodilator FEV1
(litres)
1.25 (0.07) 1.21 (0.07)
Percentage of predicted
postbronchodilator FEV1
50.29 (2.71) 45.20 (2.13)
GOLD stage I, n (%) 7 (10.3) 2 (2.9)
GOLD stage II, n (%) 22 (32.4) 23 (32.9)
GOLD stage III, n (%) 28 (41.2) 31 (44.3)
GOLD stage IV, n (%) 11 (16.2) 14 (20.0)
Values represent mean (SD), unless stated otherwise.
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These study results confirm previously published posi-
tive results by Davison et al17 and Nicholson et al,18 but
these two studies were either not randomised 17 or
included a small number of patients.18 We found no sig-
nificant difference in CCQ scores, which corresponds
with the findings of Davies et al 9 and Hernandez et al,16
who found no differences in disease-specific quality
of life measured with the St George’s Respiratory
Questionnaire. Furthermore, our results are in line with
those of earlier studies involving specialised hospital-
based nurses.9–12 15 16 25 26 The readmission rate in our
study was 25%, which is comparable to the 30% in previ-
ously published studies.9–11 Characteristics like age,
smoking history and living situation of patients in our
study were similar to those in studies from the UK 9–12
and to that of a survey on hospital-at-home services in
British hospitals by Quantrill et al.27
Earlier studies did not measure the impact of
hospital-at-home on generic health-related quality of life.
We found a significant difference between the two
groups, in favour of usual hospital care, at the end of the
hospital and home treatment. This difference had disap-
peared after 3 months. The utility scores are in line with
O’Reilly et al,28 but they found much worse scores at
admission than in our study, probably because we did not
include patients with more severe exacerbations. Utility
and CCQ scores in both groups follow the same pattern.
The greater improvement in CCQ and EQ-5D scores of
the usual hospital care group at the end of the hospital
treatment in comparison with the early discharge group
may reflect a true difference in recovery, in which case
usual hospital care is the preferred treatment. However,
an alternative explanation could be that patients who
were discharged early were confronted with their symp-
toms and limitations earlier and more intensely when
they tried to pick up normal life at home. Furthermore,
some patients have difficulties viewing hospital care fol-
lowed by early discharge as one treatment period.29
Expecting to be in a certain state at discharge, and
experiencing this is not the case, might be expressed in
worse scores on the CCQ and the EQ-5D.
In our trial multiple hospitals participated with differ-
ent socioeconomic and geographic characteristics, which
make it likely that our sample is representative of eligible
patients. The percentage of admissions initially consid-
ered to be eligible for early discharge at admission was
similar to that of previous studies (±37%). Early discharge
is possible when the exacerbation is the main problem
and comorbidities are (relatively) stable. The percentage
of patients living alone suggests that this is not an abso-
lute reason for exclusion, provided that patients have a
sufficiently functioning social support system. Still, 25%
of screened patients were considered ineligible, because
of living in a nursing home, overburden of informal care-
giver(s) or living alone with insufficient social support.
This suggests that social environment is an important
factor when deciding for admission and (early) dis-
charge. Finally, 37% of screened patients were ineligible
because of comorbidities.
Considering the very low number of treatment failures
in the early discharge group it might be possible to relax
the inclusion criteria and randomisation criteria. In our
Table 5 Readmissions during follow-up
Usual
hospital
care
Early assisted
discharge
Patients with readmission 17 (25) 17 (24)
Patients with one, two or ≥ three readmissions
One readmission 11 12
Two readmissions 4 3
Three or more
readmissions
2 2
Average (SD) time to first
readmission in days
61 (36.5) 69 (33.8)
Values are numbers of patients (%).
Table 4 Unadjusted mean (SD) CCQ total scores at each
time of measurement by treatment group
Time of
measurement
Usual hospital
care
Early assisted
discharge
T-2 days 3.21 (1.07) 3.49 (1.07)
T0 2.22 (0.97) 2.63 (1.06)
T+4 days 2.00 (1.09) 2.55 (1.21)
T+90 days 2.41 (1.14) 2.70 (1.32)
CCQ total score range is 0–6; 0 represents best possible score
and 6 represents worst possible score.
CCQ, clinical chronic obstructive pulmonary disease
queationnaire.
Figure 2 Clinical chronic obstructive pulmonary disease
questionnaire total score, differences in mean change from
baseline. Error bars represent standard errors. p Values are
based on repeated measures analysis, adjusted for baseline
value.
*Number of patients at T+4 days who completed
questionnaire that produced a valid total score; **Number of
patients at T+90 days who completed questionnaire that
produced a valid score.
Note: for interpretation reasons the sign of the CCQ has been
reversed. Positive change in CCQ scores represents
improvement in the patient's condition, which is a decrease in
CCQ score.
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trial, criteria were applied very strictly for safety reasons,
but more patients with comorbidities might be eligible in
daily practice. Furthermore, the strict review and exclusion
of patients at day 1 of admission (eg, those treated with
NIV), precluded patients from early discharge even if they
had become eligible at day 3 of admission. Therefore,
review of eligibility for early discharge should be per-
formed after a few days of hospital treatment. Thirty per
cent of patients who consented to participate were not ran-
domised because they showed insufficient recovery and/or
were depending on oxygen supply. Unlike in the British
hospital-at-home schemes, patients were not sent home
with nebulisers or oxygen cylinders, unless these were
already part of their treatment. Extension of the treatment
possibilities at home may enable early discharge of patient
with more severe disease. However, it would also require
more expertise of the nursing staff supervising patients at
home, which might currently not be present in
community-based home care organisations. Future
research should focus on determining which treatments
can be safely provided at home, which treatments require
the supervision of generic or specialised nurses and which
criteria should be applied for selecting eligible patients. In
addition, a direct comparison between early discharge
with generic and early discharge with specialised nursing
care would provide more information on which scheme is
most safe and effective.
Our study has some limitations. First, in total 139
patients were randomised, where a number of 165 was
calculated to be needed to detect a difference of 0.4 in
CCQ change scores between the two groups. A post hoc
power analysis with these 139 patients and the actual var-
iances in CCQ scores showed that the power to detect a
difference in change from baseline of 0.4 between the
groups was 73% instead of 80%, which was aimed for.
We believe that this slight reduction in power does not
have a substantial influence on our final results, because
the difference between the groups was only 0.29. It is
highly unlikely that this difference would have increased
to the clinically relevant difference of 0.4 with an add-
itional 26 patients. In previous randomised studies of
early discharge in patients diagnosed with COPD
numbers varied between 25 and 222, and only 15–35%
of admitted patients was randomised.9–12 16 30 Second,
our study was not an equivalence trial, which would
determine best whether hospital care and early dis-
charge care are equally effective. However, in order to
demonstrate equal effectiveness with CCQ score, over
500 patients would have been needed, which is beyond
what is attainable in this population. Third, 16% of
patients dropped out after randomisation. However,
comparison of patients who dropped out with patients
who completed the study only revealed more comorbid-
ities for those who dropped out. CCQ scores were not
different. Fourth, although our variable selection for
the analyses is justifiable, treatment centre could also be
considered as an important covariate in the analyses,
based on the randomisation design of the study.
However, adding treatment centre as additional fixed
factor to the analyses did not result in different out-
comes in any of the analyses. It was therefore omitted
and the analyses remained unchanged. Finally, due to
the nature of the intervention, patients and healthcare
staff could not be blinded to the allocated group.
In conclusion, we found no significant short-term or
long-term differences in outcomes between early discharge
and usual hospital care, except for generic health-related
quality of life at the end of treatment (T+4 days). Early
assisted discharge with home visits by community nurses
can reduce length of hospital stay for a selected group of
patients admitted with a COPD exacerbation and is an
alternative to usual hospital care. The decision to imple-
ment early assisted discharge with community nursing
does not only depend on the results of the effectiveness
analysis. Costs and cost-effectiveness evaluations are of high
importance as well. An economic evaluation is currently
being performed and results will be published separately.
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